



US009409873B2

(12) **United States Patent**
Porter et al.

(10) **Patent No.:** **US 9,409,873 B2**
(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **CDKI PATHWAY INHIBITORS AND USES THEREOF**

(71) Applicant: **Senex Biotechnology Inc.**, Columbia, SC (US)

(72) Inventors: **Donald C Porter**, Columbia, SC (US);
Igor B Roninson, Lexington, SC (US);
Mark P Wentland, Watervillet, NY (US)

(73) Assignee: **SENEX BIOTECHNOLOGY INC.**, Columbia, SC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/923,872**

(22) Filed: **Jun. 21, 2013**

(65) **Prior Publication Data**
US 2014/0378683 A1 Dec. 25, 2014

Related U.S. Application Data

(63) Continuation of application No. 12/956,420, filed on Nov. 30, 2010, now Pat. No. 8,598,344.

(60) Provisional application No. 61/264,991, filed on Nov. 30, 2009, provisional application No. 61/323,400, filed on Apr. 13, 2010.

(51) **Int. Cl.**
C07D 239/94 (2006.01)
C07D 403/12 (2006.01)

(52) **U.S. Cl.**
CPC *C07D 239/94* (2013.01); *C07D 403/12* (2013.01)

(58) **Field of Classification Search**
CPC *C07D 239/94*
USPC *544/293, 284*
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2012/0071477 A1* 3/2012 Porter et al. 514/234.5
* cited by examiner

Primary Examiner — Taofiq A Solola
(74) *Attorney, Agent, or Firm* — Wayne A. Keown; Verrill Dana LLP

(57) **ABSTRACT**

The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.

4 Claims, 10 Drawing Sheets